前列腺素类药物治疗青光眼的最小成本分析
x

请在关注微信后,向客服人员索取文件

篇名: 前列腺素类药物治疗青光眼的最小成本分析
TITLE:
摘要:

目的:探讨前列腺素类药物在青光眼治疗中的疗效与经济性,为临床用药提供参考。方法:回顾性选择青光眼患者790

例,按所用药物方案不同分为拉坦前列素组62 例、曲伏前列素组356 例、贝美前列素组372 例,分别采用对应药物进行治疗,计算3

组方案的临床总有效率,并运用最小成本法进行药物经济学评价。结果:拉坦前列素组、曲伏前列素组、贝美前列素组患者的总有

效率分别为87.10%、84.27%、76.08%,差异无统计学意义(P>0.05);成本分别为208.00、225.00、173.00 元,贝美前列素组的成本

最低。敏感度分析结果与最小成本分析结果一致。结论:针对青光眼的治疗,贝美前列素较拉坦前列素和曲伏前列素更经济。

ABSTRACT:

OBJECTIVE:To investigate the curative effect and economics of prostaglandins drugs in the treatment of glaucoma,

and to provide reference for clinical medication. METHODS:In retrospective study,a total of 790 glaucoma patients were divided

into latanoprost group(62 cases),travoprost group(356 cases)and bimatoprost group(372 cases)according to therapy regimen.

They were given relevant medicine. Total effective rate of 3 groups were calculated,and the cost-minimization method was

used for pharmacoeconomics evaluation. RESULTS:The total effective rate of 3 groups were 87.10%,84.27%,76.08% respectively,

without statistical significance(P>0.05). The cost of them were 208.00 yuan,225.00 yuan and 173.00 yuan,and that of bimatoprost

group was the lowest. The results of sensitivity analysis was in line with that of cost-minimization analysis. CONCLUSIONS:

For glaucoma,bimatoprost is more economical than latanoprost and travoprost.

期刊: 2015年第26卷第35期
作者: 胡月,刘子琦,张春雨,马满玲
AUTHORS: HU Yue,LIU Zi-qi,ZHANG Chun-yu,MA Man-ling
关键字: 前列腺素类药物;贝美前列素;拉坦前列素;曲伏前列素;青光眼;经济性;最小成本分析
KEYWORDS: Prostaglandins drugs;Bimatoprost;Latanoprost;Travoprost;Glaucoma;Economics;Cost-minimization analysis
阅读数: 505 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!